Vice President, Strategy & Business Development - Advanced Therapeutics Division at Agilent Technologies in Santa Clara, CA

Job description

Job Description The Role Agilent is seeking an enterprise leader for its Advanced Therapeutics Division, a specialty CDMO platform spanning RNA oligonucleotide manufacturing in Colorado and BioVectra in Canada. The approximately $600 million business serves pharmaceutical and biotechnology customers from early development through commercial-scale manufacturing and is a significant LDG growth platform. The Vice President, Strategy and Business Development is an enterprise executive role with full P&L accountability and end-to-end responsibility for the division's growth, performance and strategic development. The mandate spans commercial growth, portfolio and technology strategy, early R&D, strategic marketing, customer alliances, capital allocation and M&A. This leader will shape where Agilent competes, build a predictable revenue pipeline, allocate resources behind the most compelling opportunities and create an integrated organization capable of sustained, profitable growth. The successful leader will convert differentiated scientific and manufacturing capabilities into a predictable revenue pipeline, focus the portfolio on the most attractive opportunities, and connect strategy and customer commitments to capacity, technical delivery, quality and economics. Key Responsibilities P&L Ownership & Business Leadership Own the full P&L and overall performance of ATD, with accountability for revenue growth, pr ofitability, margin expansion, cash generation and return on invested capital. Set and continually evolve the multiyear growth agenda, translating strategy into focused operating priorities, resource choices and measurable outcomes. Establish a rigorous operating cadence using data, KPIs and leading indicators across commercial pipeline, program execution, productivity, innovation, quality and financial performance; balance near-term delivery with long-term investment. Commercial Growth & Revenue Pipeline Own the global business-development strategy and revenue opportunity pipeline end-to-end, from market development and lead generation through qualification, contracting, program award, scale-up and commercial handoff. Build a systematic, data-driven commercial engine that improves pipeline quality, deal velocity, conversion, forecast accuracy and expansion within strategic accounts. Develop deep relationships with senior pharmaceutical and biotechnology decision makers, personally lead the most consequential opportunities, and ensure customer commitments align with capability, capacity, quality, capital needs and long-term economics. Strategic Customers, Alliances & External Leadership Build durable alliances with key customers, technology partners and platform collaborators, positioning Agilent as a preferred development and manufacturing partner. Develop a high-value network of scientific leaders and key opinion leaders and represent Agilent with authority at major customer engagements, industry forums and scientific conferences. Create mechanisms that translate external customer, scientific and market insight into portfolio, R&D and investment decisions. Portfolio, Marketing & Early R&D Define short- and long-term portfolio strategy across RNA oligonucleotides, BioVectra and relevant adjacent modalities, identifying where Agilent can build differentiated and defensible leadership positions. Oversee early-stage R&D and technology investment priorities, ensuring innovation addresses important customer problems and commercially attractive emerging modalities. Own strategic marketing, segmentation, positioning and market development; assess modality mix, service-line expansion, capacity needs and technology evolution to determine where to invest, partner, acquire or deprioritize. Capital Allocation & M&A In close collaboration with Global Operations, drive the strategic capital-allocation agenda across manufacturing capacity, technology platforms, R&D and commercial capability using disciplined strategic and financial criter